Trial Search Results

A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis

The purpose of this study is to evaluate the long-term effects of orally administered SAR302503 (TG101348) in patients with myelofibrosis who have completed the MF-TG101348-001 study.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Sanofi

Stanford Investigator(s):

Intervention(s):

  • Drug: SAR302503 (TG101348)

Phase:

Phase 1/Phase 2

Eligibility


Inclusion Criteria:

   - Completion of MF-TG101348-001 study

   - Diagnosis of myelofibrosis

   - At least 18 years of age

Exclusion Criteria:

   - Any acute or chronic medical abnormality that may increase the risk associated with
   study participation

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
650-498-7061
Not Recruiting